News

The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult ...
Pharmaceutical Technology on MSN6d
FDA approves GSK’s Nucala to treat COPD
GSK respiratory, immunology and inflammation research and development (R&D) global head and senior vice-president Kaivan ...
The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...
The U.S. Food and Drug Administration has approved Nucala as a supplementary treatment for elderly individuals with severe ...
The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic ...
While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...
The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...
Patients were randomised 1:1 to receive Nucala 100mg or placebo subcutaneously every four weeks in addition to standard ...
The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...
GSK’s blockbuster respiratory drug Nucala was approved Thursday for certain patients with chronic obstructive pulmonary ...
GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence.
Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil ...